SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
18.70
+0.18 (0.97%)
Jun 27, 2025, 5:29 PM CET
159.72%
Market Cap 784.14M
Revenue (ttm) n/a
Net Income (ttm) -82.18M
Shares Out 49.01M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 166,871
Average Volume 225,926
Open 18.68
Previous Close 18.52
Day's Range 18.30 - 19.16
52-Week Range 6.96 - 23.45
Beta 0.99
RSI 59.19
Earnings Date Aug 20, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.